| Merrion Pharmaceuticals Plc, a publicly listed product development company, announced the commencement of an oral drug delivery feasibility and option agreement with Rebel Pharmaceuticals, LLC, on two undisclosed compounds. The agreement will evaluate the ability of Merrion's patented Gipet technology to enhance the compounds clinical profile and provide a substantially improved product. |
| On successful completion of the feasibility agreement, Merrion and Rebel Pharmaceuticals will enter into license agreements, the financial terms, including milestones and royalties have already been agreed. Rebel Pharmaceuticals is a speciality pharmaceuticals company focused on enhancing approved drugs using proven and patented drug delivery technologies. |
| Commenting on the announcement, John Lynch, CEO, Merrion Pharmaceuticals said "we are very pleased to be entering into this agreement with Rebel Pharmaceuticals and building a relationship with them. We believe there can be substantial patient benefits from improved oral formulations of these compounds using our unique Gipet technology". |
No comments:
Post a Comment